Showing results (451-460 of 513) with videos related to

Sort By:
Pageof 52
Journal of the American Academy of Dermatology|January 16, 2018
Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis FoundationScott M Whitlock, Clinton W Enos, April W Armstrong, et al.
JAMA Dermatology|February 26, 2025
Validation of DermSat-7 for Assessing Treatment Satisfaction in Patients With PsoriasisApril W Armstrong, Kathryn Lee, Danielle Yee, et al.
Critical Care (London, England)|December 29, 2019
Driving pressure is not associated with mortality in mechanically ventilated patients without ARDSMichael J Lanspa, Ithan D Peltan, Jason R Jacobs, et al.
Nature Medicine|October 6, 2025
Sonelokimab, an IL-17A/IL-17F-inhibiting nanobody for active psoriatic arthritis: a randomized, placebo-controlled phase 2 trialIain B McInnes, Laura C Coates, Philip J Mease, et al.
The British Journal of Dermatology|September 9, 2022
Safety of tralokinumab in adult patients with moderate-to-severe atopic dermatitis: pooled analysis of five randomized, double-blind, placebo-controlled phase II and phase III trialsEric L Simpson, Joseph F Merola, Jonathan I Silverberg, et al.
The Journal of Clinical Investigation|January 16, 2019
Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosusRichard Furie, Victoria P Werth, Joseph F Merola, et al.
JAMA Dermatology|June 26, 2020
Creation and Validation of Classification Criteria for Discoid Lupus ErythematosusScott A Elman, Cara Joyce, Kara Braudis, et al.
Rheumatology and Therapy|August 31, 2024
Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 StudiesPhilip J Mease, Joseph F Merola, Yoshiya Tanaka, et al.
Rheumatology and Therapy|May 10, 2025
Summary of Research: Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 StudiesPhilip J Mease, Joseph F Merola, Yoshiya Tanaka, et al.
Rheumatology Advances in Practice|November 15, 2021
Change in psoriatic arthritis outcome measures impacts SF-36 physical and mental component scores differently: an observational cohort studyMarie Skougaard, Tanja S Jørgensen, Mia J Jensen, et al.
Pageof 52